Mhairi C. Immermann


Immermann, Mhairi
Counsel Mhairi Immermann focuses her practice on complex corporate matters, including banking, mergers and acquisitions and capital markets transactions, for companies at all stages of growth. She has extensive experience advising administrative agents, lenders and borrowers in connection with syndicated term loan, revolving loan, asset-based loan and letter-of-credit facilities. Ms. Immermann has also represented underwriters and issuers in various phases of debt and equity securities offerings, including initial public offerings, follow-on equity offerings, investment grade and high yield bond offerings and private placements. In addition, she represents emerging companies with respect to a wide range of issues including initial organization and incorporation matters, financings and sales transactions.

Prior to joining WilmerHale, Ms. Immermann was an associate at Davis Polk & Wardwell LLP.

Publications & News


February 8, 2018

WilmerHale Advises on the Formation of Valence Media, a New Diversified Media Company

WilmerHale served as legal counsel in connection with the creation of Valence Media, a new diversified media company formed through the combination of three successful media companies: Billboard-Hollywood Reporter Media Group, dick clark productions and MRC.

December 29, 2017

WilmerHale Represents Arsanis in Closing of Initial Public Offering

Arsanis, Inc., a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, announced the closing of its initial public offering of 4,600,000 shares of its common stock at a public offering price of $10 per share, including 600,000 additional shares of common stock issued upon the exercise in full by the underwriters of their over-allotment option.

November 14, 2017

WilmerHale Reps Apellis Pharmaceuticals in Initial Public Offering

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced the closing of its initial public offering.

August 30, 2017

WilmerHale Reps Apellis Pharmaceuticals in $60 Million Series E Financing

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the treatment of autoimmune diseases, announced the closing of a $60 million Series E preferred stock financing.

April 26, 2017

WilmerHale Counsels Syros Pharmaceuticals in $35M Private Placement

Syros Pharmaceuticals, a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, announced that it has entered into a stock purchase agreement with several institutional accredited investors.

September 22, 2016

WilmerHale Advises Agios Pharmaceuticals in $173M Public Offering and Full Exercise of Option to Purchase Additional Shares

The WilmerHale team was led by Partner Steven Singer and included Special Counsel Cynthia Mazareas, Senior Associate Mhairi Immermann and Associate Brett Bromann.

June 30, 2016

WilmerHale Reps The Muse in $16M Round of Financing by Icon Ventures

The Muse, an online career resource targeting millennials, with more than 50 million users per year, announced that the company has closed a $16 million round of financing led by Icon Ventures.

June 2, 2016

WilmerHale Counsels State Street in $1.5B Debt Offering

State Street Corporation, one of the world's leading providers of financial services to institutional investors, including investment servicing, investment management and investment research and trading, recently announced a $1.5 billion debt offering.


Skip Navigation Links.


JD, magna cum laude, Georgetown University Law Center, 2011, Managing Editor, The Tax Lawyer

BA, Government and Latin American Literature, cum laude, Dartmouth College, 2008

Bar Admissions

New York

Skip Navigation Links.